/ZBH
Zimmer Biomet Holdings, Inc.
ZBH • NYSEZBH • NYSE • Healthcare
$90.35-2.35%-2.17
$90.35-2.35%(-2.17)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
67Bullish
Risk
96Low Risk
Momentum
39Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
61.6%▼9.8pp
Revenue after COGS
Operating
16.5%▼0.2pp
After operating expenses
Net
8.6%▼3.2pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
25.2
Price vs earnings
EV/EBITDA
11.2
Enterprise value
FCF Yield
8.3%
Cash generation
Earnings Yield
4.0%
Inverse of P/E
Capital Efficiency
5
GoAI Quality ScoreWeak
ROEReturn on Equity
5.6%Fair
ROAReturn on Assets
3.1%Fair
ROICReturn on Invested Capital
5.5%Fair
Financial Health
Current RatioHealthy
1.98
Short-term solvency (>1.5)
Net Debt / EBITDAHigh
3.12x
Debt repayment capacity (<3x)
Income QualityStrong
2.41
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $8.23B | $7.68B | $7.39B | $6.94B | $6.83B |
| Gross Profit | $5.07B | $5.49B | $5.31B | $4.92B | $4.87B |
| Gross Margin | 61.6% | 71.5% | 71.8% | 70.9% | 71.3% |
| Operating Income | $1.36B | $1.29B | $1.28B | $696.30M | $860.30M |
| Net Income | $705.20M | $903.80M | $1.02B | $231.40M | $401.60M |
| Net Margin | 8.6% | 11.8% | 13.8% | 3.3% | 5.9% |
| EPS | $3.56 | $4.45 | $4.91 | $1.10 | $1.93 |
Average Price Target
$105.60▲ 16.9% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Zimmer Biomet Holdings, Inc., the average price target is $105.60, with a high forecast of $122.00 and a low forecast of $89.00. The average price target represents a 16.9% increase from the current price of $90.35.
Highest
$122.00
Average
$105.60
Lowest
$89.00
Rating Distribution
Strong Buy
0
0%
Buy
18
44%
Hold
20
49%
Sell
3
7%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays● Maintain
Underweight
2026-02-12Citigroup● Maintain
Neutral
2026-02-11Wells Fargo● Maintain
Equal Weight
2026-02-11Needham● Maintain
Hold
2026-02-10BTIG● Maintain
Buy
2026-02-10UBS● Maintain
Sell
2026-01-28Bernstein● Maintain
Market Perform
2026-01-09BTIG● Maintain
Buy
2026-01-08Evercore ISI Group▲ Upgrade
In Line→Outperform
2026-01-05Baird▼ Downgrade
Outperform→Neutral
2025-12-16Earnings History & Surprises
BEAT RATE
83%
Last 18 quarters
AVG SURPRISE
+3.8%
EPS vs Estimate
BEATS / MISSES
15/1
2 met exactly
LATEST EPS
$2.42
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+0.8%
$2.42 vs $2.40
Q4 '25
+1.6%
$1.90 vs $1.87
Q3 '25
+4.5%
$2.07 vs $1.98
Q2 '25
+2.3%
$1.81 vs $1.77
Q1 '25
+0.4%
$2.31 vs $2.30
Q4 '24
$1.74 vs $1.74
Q3 '24
+1.0%
$2.01 vs $1.99
Q2 '24
+3.7%
$1.94 vs $1.87
Q1 '24
+2.3%
$2.20 vs $2.15
Q4 '23
+3.8%
$1.65 vs $1.59
Q3 '23
$1.82 vs $1.82
Q2 '23
+13.9%
$1.89 vs $1.66
No investor questions available.
Latest News
No news available